Coronary Stents

Coronary Stents

Global Coronary Stents Market to Reach US$13.0 Billion by 2030

The global market for Coronary Stents estimated at US$8.9 Billion in the year 2023, is expected to reach US$13.0 Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2023-2030. Drug Eluting Stents, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$9.2 Billion by the end of the analysis period. Growth in the Other Types segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 7.4% CAGR

The Coronary Stents market in the U.S. is estimated at US$2.6 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 7.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Coronary Stents Market - Key Trends & Drivers Summarized

Coronary stents are small, expandable tubes that are inserted into narrowed or blocked coronary arteries to restore blood flow to the heart. These devices play a crucial role in the treatment of coronary artery disease (CAD), which is a leading cause of morbidity and mortality worldwide. Stents help to keep the arteries open after procedures such as angioplasty, where a balloon is used to widen the artery. There are different types of coronary stents, including bare-metal stents (BMS), drug-eluting stents (DES), and bioresorbable stents. Drug-eluting stents are coated with medication that helps prevent the re-narrowing of the artery, while bioresorbable stents gradually dissolve after providing support to the artery.

The development and evolution of coronary stents have been driven by advancements in medical technology and materials science. Early bare-metal stents provided structural support but were associated with a higher risk of restenosis, or re-narrowing of the artery. The introduction of drug-eluting stents significantly reduced this risk by releasing antiproliferative drugs that inhibit the growth of scar tissue. More recently, bioresorbable stents have been developed to provide temporary support and then dissolve, potentially reducing long-term complications. Innovations in stent design, such as thinner struts and enhanced flexibility, have improved the deliverability and performance of stents, making them safer and more effective. Furthermore, advances in imaging and diagnostic technologies have enhanced the precision of stent placement, improving patient outcomes.

The growth in the coronary stent market is driven by several factors. Firstly, the increasing prevalence of coronary artery disease, driven by factors such as aging populations, unhealthy lifestyles, and rising rates of obesity and diabetes, is boosting the demand for stents. Secondly, advancements in stent technology, including the development of next-generation drug-eluting stents and bioresorbable stents, are driving market growth by offering improved safety and efficacy. Thirdly, the expansion of healthcare infrastructure and access to advanced medical treatments in emerging economies is increasing the adoption of coronary stents. Additionally, the growing awareness among patients and healthcare providers about the benefits of minimally invasive procedures for treating CAD is supporting market expansion. Lastly, supportive government policies, healthcare funding, and reimbursement frameworks are facilitating the adoption of advanced stent technologies, ensuring better patient care and driving market growth.

Select Competitors (Total 60 Featured) -

• Abbott Cardiovascular
• B. Braun Melsungen AG
• Becton, Dickinson and Company
• Biosensors International Group Ltd.
• BIOTRONIK SE & Co. KG
• Boston Scientific Corporation
• Cook Medical Inc.
• Elixir Medical Corporation
• Lepu Medical Technology (Beijing) Co., Ltd.
• Medtronic PLC
• Meril Life Sciences Pvt. Ltd.
• Microport Scientific Corporation
• Sahajanand Medical Technologies Ltd.
• Terumo Europe N.V.
• Translumina GmbH

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.